Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

• Xavier Sáez-Llorens,
• Claudio Lanata,
• Elaine Aranguren,
• Carlos R. Celis,
• Rubelio Cornejo,
• Rodrigo DeAntonio,
• Lucie Ecker,
• Diegi Garrido,
• Ana I. Gil,
• Marina Gonzales,
• Morgan Hess-Holtz,
• Geert Leroux-Roels,
• Helga Junker,
• Sarah-Katharina Kays,
• Sven D. Koch,
• Sandra Lazzaro,
• Philipp Mann,
• Gianluca Quintini,
• Barkha Srivastava,
• Dominik Vahrenhorst,
• Philipp von Eisenhart-Rothe,
• Olaf-Oliver Wolz,
• Lidia Oostvogels

Affiliations

Xavier Sáez-Llorens

Cevaxin, The Panama Clinic, Panama City, Panama; Corresponding author.

Claudio Lanata

Instituto de Investigación Nutricional, Lima, Peru

Elaine Aranguren

Cevaxin, The Panama Clinic, Panama City, Panama

Carlos R. Celis

Instituto de Investigación Nutricional, La Molina, Peru

Rubelio Cornejo

Instituto de Investigación Nutricional, Lima, Peru

Rodrigo DeAntonio

Cevaxin, The Panama Clinic, Panama City, Panama

Lucie Ecker

Instituto de Investigación Nutricional, Lima, Peru

Diegi Garrido

Cevaxin, The Panama Clinic, Panama City, Panama

Ana I. Gil

Instituto de Investigación Nutricional, La Molina, Peru

Marina Gonzales

CureVac AG, Tübingen, Germany

Morgan Hess-Holtz

Cevaxin, The Panama Clinic, Panama City, Panama

Geert Leroux-Roels

Ghent University Hospital, Ghent, Belgium

Helga Junker

CureVac AG, Frankfurt, Germany

Sarah-Katharina Kays

Ghent University Hospital, Ghent, Belgium

Sven D. Koch

CureVac AG, Tübingen, Germany

Sandra Lazzaro

CureVac AG, Tübingen, Germany

Philipp Mann

CureVac AG, Frankfurt, Germany

Gianluca Quintini

CureVac AG, Tübingen, Germany

Barkha Srivastava

CureVac AG, Tübingen, Germany

Dominik Vahrenhorst

CureVac AG, Tübingen, Germany

Philipp von Eisenhart-Rothe

CureVac AG, Tübingen, Germany

Olaf-Oliver Wolz

CureVac AG, Tübingen, Germany

Lidia Oostvogels

CureVac AG, Frankfurt, Germany